SLC5A2 and hydrops fetalis: In analyses restricted to people without DM, for every 1000 participants treated for one year, allocation to an SGLT-2 inhibitor was estimated to prevent 33 HF hospitalizations or cardiovascular deaths in people with HFrEF, and prevent 15 such outcomes in corresponding analyses for HFpEF (Supplemental Table 3).